Edition:
India

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

2.27USD
11:16pm IST
Change (% chg)

$0.01 (+0.44%)
Prev Close
$2.26
Open
$2.26
Day's High
$2.30
Day's Low
$2.26
Volume
6,880
Avg. Vol
28,193
52-wk High
$12.80
52-wk Low
$2.06

Latest Key Developments (Source: Significant Developments)

Pain Therapeutics Q1 Loss Per Share $0.33
Wednesday, 9 May 2018 

May 9 (Reuters) - Pain Therapeutics Inc ::PAIN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ON REMOXY® ER.Q1 LOSS PER SHARE $0.33.  Full Article

Pain therapeutics reports Q3 loss per share $0.40
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Pain Therapeutics Inc :Pain therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.40.Pain Therapeutics Inc - ‍still expects net cash usage in calendar year 2017 may be approximately $10 million​.Pain Therapeutics - ‍following resubmission of Remoxy NDA in Q1 2018, Co believes net cash usage in 2018 will decrease significantly compared to 2017.  Full Article

Pain Therapeutics announces upcoming meeting with FDA
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics announces upcoming meeting with FDA.Pain Therapeutics - ‍U.S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain​.Pain Therapeutics Inc - ‍meeting is planned for November 14, 2017 at FDA headquarters​.Pain Therapeutics Inc - ‍remoxy NDA remains on-track for a planned resubmission in Q1 2018​.  Full Article

Pain Therapeutics announces positive regulatory guidance for Remoxy ER
Tuesday, 21 Mar 2017 

Pain Therapeutics Inc : Pain Therapeutics announces positive regulatory guidance for Remoxy ER . Believe its now on track to make expeditious progress toward resubmission of Remoxy NDA . Pain Therapeutics Inc - expect to complete remoxy studies by year-end 2017, at a cost of approximately $3 mln-$4 mln .Agreement reached with FDA on additional studies that are needed for Remoxy's approval.  Full Article

Pain Therapeutics announces positive regulatory guidance for Remoxy ER
Tuesday, 21 Mar 2017 

Pain Therapeutics Inc : Pain Therapeutics announces positive regulatory guidance for Remoxy ER . Believe its now on track to make expeditious progress toward resubmission of Remoxy NDA . Pain Therapeutics Inc - expect to complete remoxy studies by year-end 2017, at a cost of approximately $3 mln-$4 mln .Agreement reached with FDA on additional studies that are needed for Remoxy's approval.  Full Article

BRIEF-Pain Therapeutics Q1 Loss Per Share $0.33

* PAIN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ON REMOXY® ER